Background and Purpose-This study aims to describe the relationship between computed tomographic (CT) perfusion (CTP)-to-reperfusion time and clinical and radiological outcomes, in a cohort of patients who achieve successful reperfusion for acute ischemic stroke.
R
educing the time to reperfusion has become a major focus in the delivery of endovascular therapy for patients with acute ischemic stroke because time is a recognized predictor of clinical outcome. [1] [2] [3] The HERMES collaboration (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) and ESCAPE trial (Emphasis on Minimizing CT to Recanalization Times) have reported a decrease in the probability of good clinical outcome with longer time from qualifying neuroimaging to reperfusion. 2, 3 Although these data point to a general decrement in good outcome rates with longer imaging-to-reperfusion times, it is possible that patients have variable resilience to time delays and different time windows in which endovascular therapy provides clinical benefit.
In DEFUSE 2 (Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 2), a patient cohort that maintained a high probability of functional independence over time was identifiable by the target perfusion-diffusion mismatch on magnetic resonance imaging (MRI). 4 These patients have a small ischemic core on diffusion-weighted imaging, a large volume of critical hypoperfusion (time-to-maximum of the residue function greater than 6 seconds, Tmax>6s), and a small volume of brain tissue with severe delays in bolus arrival (timeto-maximum of the residue function greater than 10 seconds, Tmax>10s). In contrast, patients with large Tmax>10s lesions showed more infarct growth and worse clinical outcomes. 5 The aim of this substudy of the CRISP (Computed Tomographic Perfusion to Predict Response in Ischemic Stroke Project) was to explore the relationship between time from imaging to reperfusion and clinical and radiological outcomes. 6 We hypothesized that the association between computed tomographic (CT) perfusion (CTP)-to-reperfusion time and the probability of functional independence is modified by the baseline CTP profile. Specifically, we hypothesized that the effect of prolonged CTP-to-reperfusion time is more deleterious among patients with the malignant mismatch (a mismatch and a large Tmax>10s lesion) than among patients with the target mismatch (a mismatch and a small Tmax>10s lesion).
Methods
The data that support the findings of this study are available on reasonable request (from M.G.L. at lansberg@stanford.edu). CRISP was an National Institutes of Health-funded, multicenter, prospective cohort study to evaluate the role of CTP in patients undergoing endovascular therapy. 6 In CRISP, all endovascular treatment and perioperative medical care decisions were at the discretion of the treating physicians. Clinical follow-up included National Institutes of Health Stroke Scale score (NIHSS) and modified Rankin Scale (mRS) assessments at 24 hours, 30 days, and 90 days after stroke. Two follow-up MRIs were required: early MRI was acquired within 36 (24±12) hours from the baseline CTP and included an magnetic resonance angiogram and perfusion-weighted imaging. A second MRI was done at day 5 after the baseline CTP (or on discharge, whichever occurred first) and included diffusion-weighted imaging, gradient echo/susceptibility-weighted imaging, and fluidattenuated inversion recovery (FLAIR) sequences. If any contraindications to MRI existed, a follow-up CTP was performed instead of MRI. Ethics approval was obtained from the institutional review board of all participating centers, and written informed consent was obtained before enrollment, from patients or their legally authorized representatives.
Study Population
Patients were eligible for CRISP if they had an acute large-vessel occlusion in the anterior circulation, were ≥18 years of age, had an NIHSS of ≥5, and could undergo CT angiography and perfusion imaging within 18 hours of symptom onset and within 90 minutes before the start of endovascular therapy. Patients with a baseline mRS >2 and pregnant patients were excluded. In this analysis, we included all patients with successful reperfusion who had evidence of salvageable tissue on baseline CTP imaging and divided them into 2 cohorts defined by the type of mismatch profile.
Definitions
Time of CTP was defined by the time of completion of the qualifying CTP sequence. Time of reperfusion was defined as the documented endovascular treatment completion time. CTP-to-reperfusion time was the number of hours between time of CTP and time of reperfusion. The ischemic core was defined by a decrease in relative cerebral blood flow to <30% of normal. Hypoperfused tissue likely to infarct in absence of reperfusion was defined by a time-to-maximum of the residue function over 6 seconds (Tmax>6s). The CTP mismatch was defined as a cerebral blood flow core <70 mL and an absolute difference between the Tmax>6s and ischemic core volumes of >15 mL and a volume ratio of >1.8. CTP mismatch was further divided into 2 perfusion profiles. Target mismatch was defined as a mismatch profile in which the Tmax>10s volume was ≤100 mL, whereas malignant mismatch had a Tmax>10s volume >100 mL.
Imaging Analysis
CRISP used the RAPID software (iSchemaView; Menlo Park, CA) at all sites for real-time processing of all CT and MR perfusion images. RAPID automatically segmented and quantified the volumes of the ischemic core, Tmax>6s, and Tmax>10s lesion volumes. All digitally subtracted angiography images were reviewed by an experienced neuroradiologist (M.P.M.). A modified thrombolysis in cerebral infarction score was assigned based on the final angiogram of the endovascular procedure. The final infarct volumes were assessed by a neuroradiologist who was blinded to clinical data, baseline imaging, and reperfusion status.
Reperfusion status was primarily determined by follow-up MR and CTP data. Successful reperfusion was defined as >50% reduction of the Tmax>6s lesion volumes between the baseline and the early follow-up perfusion studies. If neither study was technically adequate (excessive patient movement or failed contrast injection), reperfusion status was defined as a modified thrombolysis in cerebral infarction score of 2b or 3. Final infarct volume was outlined on day 5 FLAIR. Infarct growth was calculated as the difference between the infarct core on baseline CTP and the day 5 FLAIR.
Outcomes
The primary outcome for this analysis was independent functional outcome, defined as an mRS of ≤2 at 90 days. If the 90-day mRS was unavailable, the 30-day mRS was carried forward. The NIHSS and mRS were rated by certified study personnel. The 90-day mRS-the primary clinical outcome-was rated blinded to imaging and reperfusion status.
Statistical Analysis
The association between CT-to-reperfusion time, as well as other baseline patient characteristics, and the probability of functional independence was determined using univariable logistic regression. Next, to adjust for potential confounders of the association between CT-to-reperfusion time and functional independence, variables significant at the P<0.1 level in univariate analysis were entered into multivariable logistic regression models for patients with target mismatch, malignant mismatch, and for all patients with mismatch. We also adjusted for significant interactions between variables included in the multivariable models and CT-to-reperfusion time. Infarct growth and final infarct volumes were compared between cohorts using Wilcoxon rank-sum test. Associations were deemed significant at an α <0.05. All statistical analyses were performed using SAS 9.4.
Results
Between October 2011 and November 2014, 201 patients were enrolled in CRISP, 171 of whom had a mismatch on baseline CTP. Seventeen (10%) patients did not achieve reperfusion and were excluded (Table I in the online-only Data Supplement). Therefore, this study includes 154 patients with mismatch on baseline CTP and successful reperfusion after endovascular thrombectomy: 108 (70%) who met criteria for target mismatch profile and 46 (30%) for malignant mismatch profile. Other notable patient exclusions from this study are presented in Figure 1 . Baseline patient characteristics are presented in Table 1 (Table II in 
Association Between CTP-to-Reperfusion Time and Probability of Functional Independence
In the overall cohort (n=154), age and baseline NIHSS were significantly associated with probability of functional independence (Table 2) . Longer CTP-to-reperfusion time did not show a significant association with functional independence, but there was a strong trend (odds ratio, 0.65; 95% confidence interval, 0.41-1.03; adjusted P=0.06; Figure 2 ).
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Among patients with target mismatch profile, median CTP-to-reperfusion time was 1.8 (interquartile range [IQR], 1.5-2.4) hours. There was no significant association between CTP-to-reperfusion time and the probability of functional independence in the univariable analysis or after adjustment for age, NIHSS, and core volume (odds ratio, 1.06; 95% confidence interval, 0.59-1.90; adjusted P=0.84; Figure 3A ). Among patients with malignant mismatch profile, median CTP-to-reperfusion time was 1.95 (IQR, 1.6-2.5) hours. In these patients, CTP-to-reperfusion time was significantly associated with lower odds of achieving functional independence at 90 days (odds ratio, 0.08; 95% confidence interval, 0.01-0.42; adjusted P=0.003). The probability of functional independence dropped rapidly from 75%, when the patient was reperfused within 30 minutes of CTP, to <40% if CTP-toreperfusion time exceeded 2 hours ( Figure 3B ). 
Association Between Mismatch Profile and Radiological Outcomes
Discussion
This study demonstrates marked heterogeneity in the effect of CTP-to-reperfusion time on functional outcome after endovascular therapy. This analysis failed to detect an association between CTP-to-reperfusion time and the probability of recovering functional independence among patients with target mismatch on baseline CTP. Meanwhile, in patients with malignant mismatch, a longer CTP-to-reperfusion time was strongly associated with lower odds of functional independence.
We explored infarct growth as a physiologically plausible explanation for the discrepant effects of time between patients with target and malignant mismatch profiles. Compared with the target mismatch profile cohort, patients in the malignant mismatch cohort had more than double the infarct growth and final infarct volume, despite reperfusion. DEFUSE 2 showed similar findings with MRI perfusion-diffusion mismatch: malignant profiles on perfusion-weighted imaging were associated with the most rapid infarct growth and less penumbral salvage. 7 Using CTP, d'Esterre et al 8 demonstrated that severity of perfusion delay is inversely related to the available time window to salvage the hypoperfused lesion from infarction. A Tmax threshold of ≥10 seconds also seemed to be optimal in predicting infarction, especially if reperfusion occurs beyond 90 to 180 minutes after CTP. 8 The malignant mismatch profile thus seems to be a reliable biomarker of rapid progression to irreversible ischemic injury, predicting larger final infarcts and lower odds of regaining functional independence if timely reperfusion does not occur.
The effect of CT-to-reperfusion time on clinical outcome in our study is in keeping with previously published data, which support the external validity of our study. 2, 3 In our cohort of all patients with successful reperfusion, the association between CTP-to-reperfusion time and functional independence was similar to the one reported in the HERMES meta-analysis. 2 In CRISP and HERMES, the probability of functional independence was >70% when reperfusion occurs within 1 hour of imaging and then drops to <40% at 4 hours. 2 In ESCAPE, this probability showed a more rapid decline, from almost 70% with reperfusion within 1 hour of imaging to <40% with reperfusion at 2.5 hours. 3 Given the similarity in the overall populations of the ESCAPE trial, the HERMES collaboration, and the CRISP study, we propose that the target and malignant CTP mismatch profiles provide a further refinement in predicting probability of functional independence. 9 Our results do not imply that patients with a malignant mismatch profile on CTP should not undergo endovascular therapy. It is important to note that the probability of functional independence with short imaging-to-reperfusion time is comparable between patients with the malignant and target mismatch profiles. This suggests that the effect of endovascular treatment may be similar in both populations if imagingto-reperfusion times are kept short. Also, our results do not imply that patients with target mismatch profile are immune to delays in reperfusion. Infarct growth, albeit at a slower rate, continues in absence of reperfusion. Although we were unable to demonstrate an effect of CTP-to-reperfusion time on ORs and 95% CIs are presented for significant predictors in each cohort of patients with successful reperfusion. All factors associated with probability of functional independence at 90 days (P<0.05) in the univariable analysis are included in the multivariate model. CI indicates confidence interval; CTP, computed tomographic perfusion; NIHSS, National Institutes of Health Stroke Scale; and OR, odds ratio. functional outcome in patients with target mismatch, it is probable that a modest effect does exist, which we were underpowered to demonstrate. It is also possible that an effect of time could have been demonstrated if our sample had included target mismatch patients with longer CTP-to-reperfusion times. Therefore, it should be stressed that, although patients with the malignant mismatch appear particularly sensitive to treatment delays, early reperfusion will benefit all patients.
Limitations
Our study has limitations. First, in the absence of a control group, we can only determine the relationship between CT-to-reperfusion time and functional independence but not between CT-to-reperfusion time and the effect of endovascular treatment. Second, the relationship between CT-to-reperfusion time and functional independence may be influenced by variables other than CTP profile. Although we adjusted for potential confounders using multivariable analyses, it is possible that there were unknown confounders that were not adjusted for. Third, final infarct data were only available in a subset of case, although it unlikely affected the validity of the analysis, because there was no known bias in missing imaging data between the target and malignant mismatch profile cohorts, and the imaging analyses remained sufficiently powered to demonstrate differences between the cohorts. Fourth, the infarct core in our study was defined as critically decreased cerebral blood flow, based on previous studies supporting its validity compared with a diffusion-weighted imaging-based measure. An alternative definition of the ischemic core, such as one based on cerebral blood volume, may have resulted in a slightly different population with mismatch, but this would likely not have affected the overall results of the study. 10, 11 Last, day 5 FLAIR likely overestimates the final infarct volume because of the presence of vasogenic edema, but because this effect is present in both groups, it is unlikely to have affected the results of the analyses.
Conclusions
Time delay between baseline imaging and endovascular reperfusion have discrepant effects depending on patients' baseline mismatch profile. Patients with a malignant mismatch, characterized by a large territory of severely delayed contrast arrival, have a rapid decline in their chance of functional independence with longer delays, whereas patients with a target mismatch are relatively resilient, yet likely not immune to such treatment delays. Our results do not indicate a lack of treatment effect among patients with the malignant profile. However, they suggest that the treatment effect may be greater with shorter imaging-to-reperfusion times, particularly in patients with a malignant mismatch profile. 
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